Alba Atienza相关文献与解析，生知库 | 链接生命科学的每一步

Patrick Nylund ，Berta Garrido-Zabala ，Stefania Iliana Tziola ，Tabassom Mohajershojai ，Hanna Berglund ，Catharina Muylaert ，Lien Ann Van Hemelrijck ，Alba Atienza Párraga ，Louella Vasquez ，Jim Jacob ，Eric Bergquist ，José Ignacio Martín-Subero ，Fredrik Öberg ，Torbjörn Karlsson ，Marika Nestor ，Elke De Bruyne ，Antonia Kalushkova ，Helena Jernberg Wiklund

肿瘤

骨髓瘤

T细胞

发表日期：2025

文献求助收藏

Combinatorial DNMTs and EZH2 inhibition reprograms the H3K27me3 and DNAme-mediated onco-epigenome to suppress multiple myeloma proliferation

组合式DNMTs和EZH2抑制可重编程H3K27me3和DNAme介导的癌基因表观基因组，从而抑制多发性骨髓瘤增殖。

期刊:Scientific Reports

影响因子:3.8

doi:10.1038/s41598-025-17093-z

Alba Atienza Párraga #,Patrick Nylund #,Klev Diamanti,Berta Garrido-Zabala,Stefania Iliana Tziola,Louella Vasquez,Paul Theodor Pyl,Doroteya Raykova,Aron Skaftason,Anqi Ma,Jian Jin,José Ignacio Martín-Subero,Fredrik Öberg,Elke De Bruyne,Jan Komorowski,Helena Jernberg Wiklund,Antonia Kalushkova

PVT1 interacts with polycomb repressive complex 2 to suppress genomic regions with pro-apoptotic and tumour suppressor functions in multiple myeloma

PVT1 与多梳抑制复合物 2 相互作用，抑制多发性骨髓瘤中具有促凋亡和肿瘤抑制功能的基因组区域

期刊:Haematologica

影响因子:8.2

doi:10.3324/haematol.2023.282965

Patrick Nylund, Berta Garrido-Zabala, Alba Atienza Párraga, Louella Vasquez, Paul Theodor Pyl, George Mickhael Harinck, Anqi Ma, Jian Jin, Fredrik Öberg, Antonia Kalushkova, Helena Jernberg Wiklund

A distinct metabolic response characterizes sensitivity to EZH2 inhibition in multiple myeloma

多发性骨髓瘤对 EZH2 抑制剂的敏感性具有独特的代谢反应特征。

期刊:Cell Death & Disease

影响因子:8.1

doi:10.1038/s41419-021-03447-8

Patrick Nylund # ，Alba Atienza Párraga # ，Jakob Haglöf ，Elke De Bruyne ，Eline Menu ，Berta Garrido-Zabala ，Anqi Ma ，Jian Jin ，Fredrik Öberg ，Karin Vanderkerken ，Antonia Kalushkova ，Helena Jernberg-Wiklund

One Omics Approach Does Not Rule Them All: The Metabolome and the Epigenome Join Forces in Haematological Malignancies

单一的组学方法并不能包治百病：代谢组和表观基因组在血液系统恶性肿瘤中协同作用

期刊:Epigenomes

影响因子:3.5

doi:10.3390/epigenomes5040022

Kalushkova, Antonia; Nylund, Patrick; Párraga, Alba Atienza; Lennartsson, Andreas; Jernberg-Wiklund, Helena

EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions

多发性骨髓瘤中的 EZH2 抑制会下调骨髓瘤相关致癌基因并上调具有潜在肿瘤抑制功能的 microRNA

期刊:Oncotarget

影响因子:

doi:10.18632/oncotarget.14378

Mohammad Alzrigat, Alba Atienza Párraga, Prasoon Agarwal, Hadil Zureigat, Anders Österborg, Hareth Nahi, Anqi Ma, Jian Jin, Kenneth Nilsson, Fredrik Öberg, Antonia Kalushkova, Helena Jernberg-Wiklund

The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains

多梳蛋白 BMI-1 抑制剂 PTC-209 是一种有效的抗骨髓瘤药物，可单独使用或与针对 EZH2 和 BET 溴结构域的表观遗传抑制剂联合使用

期刊:Oncotarget

影响因子:

doi:10.18632/oncotarget.21909

Mohammad Alzrigat, Alba Atienza Párraga, Muntasir Mamun Majumder, Anqi Ma, Jian Jin, Anders Österborg, Hareth Nahi, Kenneth Nilsson, Caroline A Heckman, Fredrik Öberg, Antonia Kalushkova, Helena Jernberg-Wiklund

Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target

多发性骨髓瘤中组蛋白 H3 赖氨酸 27 和赖氨酸 4 三甲基化的全基因组分析揭示了 Polycomb 基因靶向的重要性，并强调了 EZH2 作为潜在治疗靶点

期刊:Oncotarget

影响因子:

doi:10.18632/oncotarget.6843

Prasoon Agarwal, Mohammad Alzrigat, Alba Atienza Párraga, Stefan Enroth, Umashankar Singh, Johanna Ungerstedt, Anders Österborg, Peter J Brown, Anqi Ma, Jian Jin, Kenneth Nilsson, Fredrik Öberg, Antonia Kalushkova, Helena Jernberg-Wiklund

Dual targeting of G9a and DNMTs induces antitumor effects in multiple myeloma

双重靶向G9a和DNMTs可诱导多发性骨髓瘤的抗肿瘤作用

Combinatorial DNMTs and EZH2 inhibition reprograms the H3K27me3 and DNAme-mediated onco-epigenome to suppress multiple myeloma proliferation

组合式DNMTs和EZH2抑制可重编程H3K27me3和DNAme介导的癌基因表观基因组，从而抑制多发性骨髓瘤增殖。

PVT1 interacts with polycomb repressive complex 2 to suppress genomic regions with pro-apoptotic and tumour suppressor functions in multiple myeloma

PVT1 与多梳抑制复合物 2 相互作用，抑制多发性骨髓瘤中具有促凋亡和肿瘤抑制功能的基因组区域

A distinct metabolic response characterizes sensitivity to EZH2 inhibition in multiple myeloma

多发性骨髓瘤对 EZH2 抑制剂的敏感性具有独特的代谢反应特征。

One Omics Approach Does Not Rule Them All: The Metabolome and the Epigenome Join Forces in Haematological Malignancies

单一的组学方法并不能包治百病：代谢组和表观基因组在血液系统恶性肿瘤中协同作用

EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions

多发性骨髓瘤中的 EZH2 抑制会下调骨髓瘤相关致癌基因并上调具有潜在肿瘤抑制功能的 microRNA

The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains

多梳蛋白 BMI-1 抑制剂 PTC-209 是一种有效的抗骨髓瘤药物，可单独使用或与针对 EZH2 和 BET 溴结构域的表观遗传抑制剂联合使用

Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target

多发性骨髓瘤中组蛋白 H3 赖氨酸 27 和赖氨酸 4 三甲基化的全基因组分析揭示了 Polycomb 基因靶向的重要性，并强调了 EZH2 作为潜在治疗靶点